$VANI
Vivani Medical, Inc. Stock $vani

$vani Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000175392624000616 Filed on March 26, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.501M	$1.509M	$9.997M
YoY Change	-5.62%	-55.09%	41.4%
% of Gross Profit
Research & Development	$3.726M	$4.708M	$16.97M
YoY Change	-5.79%	6.28%	19.75%
% of Gross Profit
Depreciation & Amortization	$99.00K	$97.00K	$357.0K
YoY Change	-8.33%	-11.82%	-6.05%
% of Gross Profit
Operating Expenses	$6.227M	$6.217M	$26.97M
YoY Change	-5.67%	-20.19%	26.95%
Operating Profit	-$6.227M		-$26.97M
YoY Change	-5.67%		26.95%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$188.0K	$191.0K	$1.313M
YoY Change	-32.86%	-60.21%	173.54%
Pretax Income	-$6.039M	-$6.026M	-$25.65M
YoY Change	-4.45%	-17.23%	84.68%
Income Tax
% Of Pretax Income
Net Earnings	-$6.039M	-$6.026M	-$25.65M
YoY Change	-4.42%	-17.23%	84.68%
Net Earnings / Revenue
Basic Earnings Per Share	$0.12
Diluted Earnings Per Share	-$0.12	-$0.12	-$0.50
COMMON SHARES
Basic Shares Outstanding	54.98M shares	51.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.65M	$20.65M	$20.65M
YoY Change	-22.12%	-54.18%	-54.18%
Cash & Equivalents	$29.65M	$20.65M	$20.65M
Short-Term Investments
Other Short-Term Assets	$1.854M	$2.408M	$2.408M
YoY Change	-28.97%	-1.71%	-1.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$31.50M	$23.06M	$23.06M
YoY Change	-22.57%	-51.48%	-51.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.689M	$1.729M	$21.35M
YoY Change	52.03%	46.28%	989.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$47.00K	$52.00K	$52.00K
YoY Change	-82.59%	-81.43%	-81.43%
Other Assets	$1.338M	$1.338M	$1.338M
YoY Change	-2.05%	-2.05%	-2.34%
Total Long-Term Assets	$22.29M	$22.74M	$22.74M
YoY Change	472.02%	531.18%	531.53%
TOTAL ASSETS
Total Short-Term Assets	$31.50M	$23.06M	$23.06M
Total Long-Term Assets	$22.29M	$22.74M	$22.74M
Total Assets	$53.79M	$45.80M	$45.80M
YoY Change	20.66%	-10.43%	-10.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$570.0K	$542.0K	$542.0K
YoY Change	-23.59%	-53.95%	-54.07%
Accrued Expenses	$1.953M	$1.727M	$5.181M
YoY Change	-7.62%	-26.76%	-8.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.138M	$5.723M	$5.723M
YoY Change	4.69%	-16.11%	-16.09%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$18.94M	$19.31M	$19.31M
YoY Change	5311.43%
Total Long-Term Liabilities	$18.94M	$19.31M	$19.31M
YoY Change	5311.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.138M	$5.723M	$5.723M
Total Long-Term Liabilities	$18.94M	$19.31M	$19.31M
Total Liabilities	$25.08M	$25.04M	$25.04M
YoY Change	303.7%	266.99%	267.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$104.5M	-$98.44M
YoY Change	32.08%	35.24%
Common Stock	$5.000K	$5.000K
YoY Change	-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$28.71M	$20.76M	$20.76M
YoY Change
Total Liabilities & Shareholders Equity	$53.79M	$45.80M	$45.80M
YoY Change	20.66%	-10.43%	-10.43%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.039M	-$6.026M	-$25.65M
YoY Change	-4.42%	-17.23%	84.68%
Depreciation, Depletion And Amortization	$99.00K	$97.00K	$357.0K
YoY Change	-8.33%	-11.82%	-6.05%
Cash From Operating Activities	-$4.512M	-$3.479M	-$23.70M
YoY Change	-35.23%	-33.22%	26.13%
INVESTING ACTIVITIES
Capital Expenditures	$182.0K	$747.0K	$887.0K
YoY Change	391.89%	1767.5%	160.88%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$182.0K	-$747.0K	-$887.0K
YoY Change	391.89%	1767.5%	160.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$13.69M	23.00K	$133.0K
YoY Change			-99.79%
NET CHANGE
Cash From Operating Activities	-$4.512M	-3.479M	-$23.70M
Cash From Investing Activities	-$182.0K	-747.0K	-$887.0K
Cash From Financing Activities	$13.69M	23.00K	$133.0K
Net Change In Cash	$8.994M	-4.203M	-$24.45M
YoY Change	-228.43%	-19.94%	-155.24%
FREE CASH FLOW
Cash From Operating Activities	-$4.512M	-$3.479M	-$23.70M
Capital Expenditures	$182.0K	$747.0K	$887.0K
Free Cash Flow	-$4.694M	-$4.226M	-$24.59M
YoY Change	-32.97%	-19.5%	28.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
CY2023	vani	Gain From Bargain Purchase GainFromBargainPurchase		usd
CY2023	vani	Cash Acquired In Merger For Stock Consideration CashAcquiredInMergerForStockConsideration		usd
CY2023	vani	Cancellation Of Safe Borrowing CancellationOfSafeBorrowing		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	vani	Establishment Of Operating Rightofuse Assets Through Operating Lease Obligations EstablishmentOfOperatingRightofuseAssetsThroughOperatingLeaseObligations		usd
CY2023	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1		usd
CY2023	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred		usd
CY2022	vani	Receivables For Cash Intransit On Exercise Of Common Stock Under Equity Incentive Plan ReceivablesForCashIntransitOnExerciseOfCommonStockUnderEquityIncentivePlan		usd
CY2022	vani	Purchase Of Property And Equipment In Accrued Expenses PurchaseOfPropertyAndEquipmentInAccruedExpenses		usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51031	shares
CY2023Q3	vani	Promissory Funding Support Term PromissoryFundingSupportTerm	P5Y
CY2022Q4	vani	Shares Underlying Restricted Stock Unit Outstanding SharesUnderlyingRestrictedStockUnitOutstanding		shares
CY2018	vani	Grant Received Funding Period GrantReceivedFundingPeriod	P5Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense		usd
CY2023	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense		usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense		pure
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions		usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions		usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions		usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent		usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y5M27D
CY2021Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5100000
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	38900000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54978000	shares
CY2023	dei	Auditor Firm AuditorFirmId	207
CY2023	dei	Auditor Name AuditorName	BPM LLP
CY2023	dei	Auditor Location AuditorLocation	Walnut Creek, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20654000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45076000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2408000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2452000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	23062000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	47528000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1729000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1182000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19616000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	779000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1338000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1366000	usd
CY2023Q4	vani	Deposits And Other Assets DepositsAndOtherAssets	52000	usd
CY2022Q4	vani	Deposits And Other Assets DepositsAndOtherAssets	275000	usd
CY2023Q4	us-gaap	Assets Assets	45797000	usd
CY2022Q4	us-gaap	Assets Assets	51130000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	542000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1177000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1727000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2358000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1675000	usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1675000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	396000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	657000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1383000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	955000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5723000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6822000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19313000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	25036000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6822000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51031	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51031	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50736	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50736	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119054000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	117054000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	140000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	35000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98438000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72786000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20761000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	44308000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45797000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51130000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16968000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14169000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9997000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7072000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	26965000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	21241000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-26965000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-21241000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1313000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7352000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-25652000	usd
CY2023	vani	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.50	shares
CY2022	vani	Net Loss Per Common Share Basic And Diluted NetLossPerCommonShareBasicAndDiluted	-0.36	shares
CY2023	vani	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	50853
CY2022	vani	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	38241
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-25652000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13889000	usd
CY2023	vani	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent01 OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent01	105000	usd
CY2022	vani	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent01 OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent01	35000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25547000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13854000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2465000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	16000	usd
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	54385000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1296000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	35000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13889000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	44308000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	44308000	usd
CY2023	vani	Stock Issued During Period Value Stock Options Warrants Exercised StockIssuedDuringPeriodValueStockOptionsWarrantsExercised	136000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1864000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	105000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-25652000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20761000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-25652000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-13889000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	357000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	381000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1864000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1296000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-121000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-904000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	36000	usd
CY2022	vani	Gain From Bargain Purchase GainFromBargainPurchase	6877000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-264000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	476000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-602000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1941000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-261000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	204000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-694000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2551000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23699000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18787000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	887000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	338000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-887000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-338000	usd
CY2022	vani	Cash Acquired In Merger For Stock Consideration CashAcquiredInMergerForStockConsideration	55374000	usd
CY2022	vani	Cancellation Of Safe Borrowing CancellationOfSafeBorrowing	8000000	usd
CY2023	vani	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	133000	usd
CY2022	vani	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	16000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	133000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	63390000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-24450000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	44264000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	46442000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2178000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21992000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	46442000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2023	vani	Establishment Of Operating Rightofuse Assets Through Operating Lease Obligations EstablishmentOfOperatingRightofuseAssetsThroughOperatingLeaseObligations	20755000	usd
CY2022	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	8000000	usd
CY2022	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	2112000	usd
CY2023	vani	Receivables For Cash Intransit On Exercise Of Common Stock Under Equity Incentive Plan ReceivablesForCashIntransitOnExerciseOfCommonStockUnderEquityIncentivePlan	3000	usd
CY2023	vani	Purchase Of Property And Equipment In Accrued Expenses PurchaseOfPropertyAndEquipmentInAccruedExpenses	132000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_zZJoej2Vp2K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><b>1. <span id="xdx_825_zHMQ1xCxDFR5">Organization and Business Operations</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Vivani Medical, Inc. (“Vivani,” the “Company,” “we,” “us,” “our” or similar terms) is a preclinical stage biopharmaceutical company which develops miniaturized, subdermal implants utilizing its proprietary NanoPortal™ technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners to address a leading cause of poor clinical outcomes in the treatment of chronic disease, medication non-adherence. According to the US Centers for Disease Control and Prevention (“CDC”), adherence is defined as the extent to which an individual’s behavior, including taking medications, corresponds to recommendations from a health care provider. For example, approximately 50% of patients treated for type 2 diabetes are medication non-adherent, which can lead to poor clinical outcomes. We are developing a portfolio of miniature, sub-dermal drug implant candidates that, unlike most oral and injectable medicines, are designed with the goal of guaranteeing medication adherence by delivering therapeutic drug levels for up to 6 months or longer. In addition, our aim is to minimize fluctuations in patients’ drug levels through the use of our NanoPortal technology, which may improve the tolerability profiles for medicines that produce side effects associated with fluctuating drug levels in the blood.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In February 2022, we announced the signing of a definitive merger agreement between Nano Precision Medical, Inc. (“NPM”) and Second Sight Medical Products, Inc. (“Second Sight” or “SSMP”), pursuant to which NPM became a wholly-owned subsidiary of Second Sight. On August 30, 2022, the merger closed and the combined company of NPM and Second Sight was renamed Vivani Medical, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In December 2022, we contributed our neuromodulation assets and certain liabilities to Cortigent, Inc. (“Cortigent”) a newly formed corporation in Delaware, and wholly-owned subsidiary of Vivani, in exchange for 20,000,000 shares of common stock of Cortigent. As of December 31, 2023, after giving effect to a 1-for-4 reverse stock split that we implemented, Cortigent had <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_dxL_uShares_c20231231_zqZFlbWOk0J4" title="Common stock, shares outstanding::XDX::51031"><span style="-sec-ix-hidden: xdx2ixbrl0400">5,000,000</span></span> shares of common stock outstanding, all owned by Vivani. While the primary focus of Vivani is to develop and ultimately commercialize our drug implant business from legacy company NPM, Vivani’s management team remains committed to identifying and exploring strategic options for the further advancement of the neuromodulation business of Cortigent which includes the development of its pioneering neurostimulation systems to help patients recover critical body functions. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In March 2023, Vivani announced the filing of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) for the proposed initial public offering of Cortigent. Cortigent, currently a wholly-owned subsidiary of Vivani, was formed for the purpose of advancing the Company’s pioneering neurostimulation technology. The Registration Statement on Form S-1 was recently amended and filed with the SEC in February 2024 to refresh the financial information and provide minor updates to the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">On July 6, 2023, Vivani changed its state of incorporation from the State of California to the State of Delaware by means of a plan of conversion, effective July 5, 2023. The reincorporation, including the principal terms of the plan of conversion, was submitted to a vote of, and approved by, Vivani’s stockholders at its 2023 Annual Meeting of Stockholders held on June 15, 2023. As part of this change of incorporation the Company established a par value of $0.0001 per share and all periods have been retroactively adjusted to reflect this change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">An Investigational New Drug Application (“IND”) for NPM-119 (GLP-1 implant) was filed with the U.S. Food and Drug Administration (“FDA”) on July 14, 2023, to support the initiation of the first-in-human study of NPM-119 in patients with type 2 diabetes, also named LIBERATE-1™. On August 18, 2023, FDA provided written notification that the LIBERATE-1 study was on full clinical hold, primarily due to insufficient Chemistry, Manufacturing, and Controls (“CMC”) information to assess the risk to human subjects. Vivani remains actively engaged in discussions with FDA as part of its efforts to lift the clinical hold and plans to submit a Complete Response to the FDA during the first half of 2024. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">On August 25, 2023, the Company and Cortigent entered into an Amendment 1 (the “Amendment”) to the Transition Funding, Support and Services Agreement dated March 19, 2023 (the “TFSSA”). Pursuant to the TFSSA, the Company has agreed to advance funds and provide or cause to be provided to Cortigent the services and funding intended to cover salaries and related costs, rent and other overhead in order to permit Cortigent to operate in substantially the same manner in which business operations of Cortigent were previously operated by Second Sight Medical Products, Inc., prior to the formation of Cortigent, which obligations will continue, in the case of the funding obligations, until the earlier of December 31, 2024 or the closing of an initial public offering of Cortigent (the “Funding Support Term”). Under the Amendment, Cortigent has agreed to repay $<span id="xdx_905_eus-gaap--RepaymentOfNotesReceivableFromRelatedParties_c20230823__20230825_zVf4l6Mi7kK7" title="Cortigent has agreed to repay">1,500,000</span> to the Company at the conclusion of the Funding Support Term. In addition, at the conclusion of the Funding Support Term, Cortigent will enter into a <span id="xdx_900_ecustom--PromissoryFundingSupportTerm_dxL_c20230823__20230825_zIvos4CU0Ryh" title="Funding support term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0404">five</span></span>-year promissory note at <span id="xdx_90B_eus-gaap--DerivativeAverageVariableInterestRate_iI_pid_dp_uPure_c20230825_zgJYw273BCmb" title="Interest rate">5</span>% interest for $<span id="xdx_909_eus-gaap--OriginationOfNotesReceivableFromRelatedParties_c20230823__20230825_zYg8zKbA7UA7" title="Cortigent enter into a promissory note">2,000,000</span> in favor of the Company. The Company will forgive any remaining amounts due by Cortigent to the Company under the TFSSA. In October 2023, Vivani implemented a reduction-in-force to conserve cash that decreased Cortigent’s employees from 14 to 7 while continuing the ongoing Orion<sup>®</sup> clinical study and basic operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">In the fourth quarter of 2023, Vivani Medical Australia Pty Ltd., a wholly-owned subsidiary in Australia was established to support studies of our products and product candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In February 2024, Vivani announced positive NPM-115 preclinical weight loss data comparable to semaglutide, the active ingredient in Ozempic<sup>®</sup>/Wegovy<sup>®</sup>, and disclosed NPM-139 as a semaglutide implant as our strategy shifted to prioritize our obesity portfolio. In a study in high-fat diet-induced obese mice, NPM-115 generated weight loss of approximately 20% compared to a sham implant control after a 28-day treatment duration, comparable to weight loss observed in mice treated with semaglutide injections (Ozempic<sup>®</sup>/Wegovy<sup>®</sup>) in the same study. The Company also disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management, with the added potential benefit of once-yearly administration.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Agreement and Plan of Merger with Nano Precision Medical, Inc.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, Second Sight entered into an agreement and plan of merger (the “Merger Agreement”) with NPM. The Merger was approved by the shareholders of Second Sight on July 27, 2022 and closed on August 30, 2022. Upon consummation of the Merger, NPM became a wholly-owned subsidiary of Second Sight. Concurrent with to the Merger, Second Sight changed its name to Vivani Medical, Inc. and changed its trading symbol from EYES to VANI, and trades under the ticker VANI on the NASDAQ market. Certain investors and members of the NPM board of directors are also investors and members of the board of directors of Second Sight.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms and conditions of the Merger Agreement, the securities of NPM converted into the right to receive shares of Second Sight’s common stock representing <span id="xdx_90C_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20231231__srt--OwnershipAxis__custom--SecondSightSwitzerlandSarlMember_zLBgliXUlOE7" title="Subsidiary, ownership percentage, parent">77.32</span>% of the total issued and outstanding shares of common stock of Second Sight on a fully converted basis, including, without limitation, giving effect to the conversion of all options, warrants, and any and all other convertible securities assuming net settlement. Second Sight filed a Registration Statement on Form S-4 on May 13, 2022, in connection with the Merger to register the merger shares effective June 24, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, in connection with the Merger, Second Sight and NPM also entered into a Simple Agreement for Future Equity (“SAFE”) whereby Second Sight provided to NPM an investment advance of $<span id="xdx_90E_eus-gaap--BusinessCombinationConsiderationTransferred1_pn6n6_c20230101__20231231_z3vvLeNC6f4" title="Purchase consideration">8</span> million. The Merger Agreement provided that the SAFE would terminate if the Merger were to be successfully completed. Under the terms of the SAFE, upon successfully completion of the Merger on August 30, 2022, the investment advance was eliminated. Under the accounting for a business combination, the $8 million adjusted the purchase consideration.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Merger involved a change of control and was accounted for as a reverse merger in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Under this method of accounting, Second Sight was treated as the “acquired” company for financial reporting purposes with NPM as the acquirer. The assets acquired and liabilities assumed by NPM were recorded at fair value under Accounting Codification Standard (“ASC”) 805, <i>Business Combinations</i>. Accordingly, <span id="xdx_905_eus-gaap--CommonStockVotingRights_c20220828__20220830_zsFomxxLCkZ3" title="Common stock, voting rights">on August 30, 2022 (the “Acquisition Date”), NPM (a calendar year-end entity) was deemed to have acquired 100% of the outstanding common shares and voting interest of Second Sight.</span> The results of Second Sight’s operations have been included in the consolidated financial statements since that date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The acquisition-date fair value of consideration transferred totaled $<span id="xdx_90E_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_dm_c20220828__20220830__us-gaap--BusinessAcquisitionAxis__us-gaap--SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_z0BS8n2e23f8" title="Fair value of the consideration transferred">54.4 million</span>, which consisted of the fair value of the <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_uShares_c20220830_zYjIPXnNxtqj" title="Common stock issued">13,136,000 </span> shares of common stock deemed issued to Second Sight shareholders, valued at the closing price per share on the acquisition date of $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20220830_zjoGT9zS88qa" title="Common stock, par or stated value per share">4.14</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p id="xdx_895_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zh4CJ2s36Mzb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span id="xdx_8BD_zNvJXq0P5G5h">The following table summarizes the fair values of the assets acquired and liabilities assumed at the acquisition date (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="text-decoration: underline">At August 30, 2022</span></td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20220830_zEm9ZEywmR3c"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_400_ecustom--CashAndCashEquivalentsFairValue_iI_pn3n3_zKdVdrl19Tyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">55,374</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentFairValueDisclosure_iI_pn3n3_zmIWb7cN4ZKd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">99</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn3n3_zeh0zrwYzYlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,657</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--OperatingLeaseRightOfUseAssetOne_iI_pn3n3_z4BPnItuvPYa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Right of use assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherAssetsFairValueDisclosure_iI_pn3n3_zl1K7TfKQrF5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">56</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueOfAssetsAcquired1_iI_pn3n3_zm139OZcoGl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total identifiable assets acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,326</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_iNI_pn3n3_di_zmUXU01xYudb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,913</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iNI_pn3n3_di_zp0AHzAW07C6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Right of use liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(151</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--FairValueOfLiabilitesAcquired_iI_pn3n3_zqkGjJFJoP8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total liabilities assumed</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,064</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pn3n3_zNIYrxWuQrGd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net identifiable assets acquired</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53,262</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zRYPiMXHXw4k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SAFE loan of $<span id="xdx_90A_eus-gaap--AssetsFairValueAdjustment_pn6n6_c20220828__20220830_z2eCZNjaOA5f" title="Assets, fair value adjustment">8.0</span> million was cancelled in the Merger which adjusted the fair value of net assets acquired.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p id="xdx_899_eus-gaap--GainLossOnInvestmentsTextBlock_zimqCSQmB0Yd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span id="xdx_8B5_zFeAV2yusqI">The following table summarizes the calculation of the gain on bargain purchase (in thousands) recorded in the year ended December 31, 2022: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20221231_zoMQk0Wf3bEj" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--TotalConsideration_iI_pn3n3_zonwZYSRrLCi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 37%; text-align: left">Total consideration</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">54,385</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AdvancesFairValueDisclosure_iNI_pn3n3_di_z83Y8Y0aLctj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">SAFE loan forgiven</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(8,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_iI_pn3n3_zLZzZqZ8Ykol" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less net identifiable assets acquired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(53,262</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_ecustom--GainOnBargainPurchase_iI_pn3n3_zVKw5CSauyE4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Gain on bargain purchase</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,877</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z85Ot2ja9DOc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because NPM purchased <span id="xdx_908_eus-gaap--SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent_pid_dp_uPure_c20220101__20221231_z7rIfDIz93r1" title="Fair value of identifiable assets acquired and liabilities">100</span>% of Second Sight and the fair value of identifiable assets acquired and liabilities assumed exceeded the fair value of the consideration, we reassessed the recognition and measurement of identifiable assets acquired and liabilities assumed and concluded that all acquired assets and assumed liabilities were properly recognized and that the valuation procedures and resulting measures were appropriate. As a result, we recognized a gain of $<span id="xdx_903_eus-gaap--OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_pn5n6_c20220101__20221231_zXoze2Lh6X1f" title="Gain of other income expenses">6.9</span> million in the year ended December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We recognized $<span id="xdx_903_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20220101__20221231_zzqf8EJKy2Gf" title="Business combination, acquisition related costs">0.7</span> million of acquisition related costs that were expensed in the twelve months ended December 31, 2022. These costs are included in the consolidated income statement in the line item entitled “General and administrative.”</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Operating expenses of Second Sight included in the consolidated statements of operations from the acquisition date August 30, 2022 to the period ending December 30, 2022 were $<span id="xdx_908_eus-gaap--UtilitiesOperatingExpenseOperations_pn5n6_c20230101__20231231_zl31kdIoxFmj" title="Business combination, operating expenses">2.1</span> million. Pro forma consolidated net loss as if Second Sight had been included in the consolidated results was $<span id="xdx_90D_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_pn5n6_c20220101__20221231__srt--StatementScenarioAxis__srt--ProFormaMember_z4PG7h2zjbxg" title="Business combination, pro forma">28.3</span> million for the year ended December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>SAFE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 4, 2022, in connection with the Merger, Second Sight and NPM also entered into a Simple Agreement for Future Equity (“SAFE”) whereby Second Sight provided to NPM an investment advance of $8 million. The agreement provided that the SAFE would terminate if the Merger were to be successfully completed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of the SAFE, upon successfully completion of the Merger on August 30, 2022, the investment advance was eliminated. Under the accounting for a business combination, the $8.0 million adjusted the purchase consideration.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-indent: 0.3in">From inception, our operations have been funded primarily through the sales of our common stock as well as from warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10pt 0pt 0; text-indent: 0.3in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with no revenue that is developing novel medical devices, including limitations on our operating capital resources. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 1, 2024, <span id="xdx_90F_eus-gaap--SecuritiesPurchasedUnderAgreementsToResellMeasurementDifferenceDescription_c20240228__20240301__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUrpRkxQSdDf" title="Description of purchase agreement">the Company entered into a Securities Purchase Agreement with an institutional investor relating to the issuance of 3,947,368 shares of the Company’s common stock, par value of $0.0001 per share and warrants to purchase up to an aggregate of 3,947,368 shares of Common Stock (the “Warrant”), to such investor at a purchase price of $3.80 per share and accompanying warrant in a registered direct offering (the “Offering”). The Warrant has an exercise price of $3.80 per share, is exercisable immediately upon issuance and will expire three years following the date of issuance.</span> The Company also entered into a Placement Agency Agreement with Maxim Group LLC, who acted as the sole placement agent for the Offering. The gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfDebt_pn5n6_c20240228__20240301__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVuTb3niZJl4" title="Gross proceeds">15.0</span> million from the Offering, before paying the placement agent fees and other estimated offering expenses, was received on March 5, 2024. For additional information, refer to Note 13. Subsequent Event of the Notes to Consolidated Financial Statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate that currently available cash will provide sufficient funds to enable the Company to meet its planned obligations into the second half of 2025. Our ability to continue as a going concern is dependent on our ability to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there can be no assurances that we will be able to do so.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>
CY2023Q3	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	1500000	usd
CY2023Q3	us-gaap	Derivative Average Variable Interest Rate DerivativeAverageVariableInterestRate	0.05	pure
CY2023Q3	us-gaap	Origination Of Notes Receivable From Related Parties OriginationOfNotesReceivableFromRelatedParties	2000000	usd
CY2023	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	8000000	usd
CY2022Q3	us-gaap	Common Stock Voting Rights CommonStockVotingRights	on August 30, 2022 (the “Acquisition Date”), NPM (a calendar year-end entity) was deemed to have acquired 100% of the outstanding common shares and voting interest of Second Sight.
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13136000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	4.14
CY2022Q3	vani	Cash And Cash Equivalents Fair Value CashAndCashEquivalentsFairValue	55374000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Fair Value Disclosure PropertyPlantAndEquipmentFairValueDisclosure	99000	usd
CY2022Q3	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1657000	usd
CY2022Q3	vani	Operating Lease Right Of Use Asset One OperatingLeaseRightOfUseAssetOne	140000	usd
CY2022Q3	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	56000	usd
CY2022Q3	vani	Fair Value Of Assets Acquired1 FairValueOfAssetsAcquired1	57326000	usd
CY2022Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3913000	usd
CY2022Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	151000	usd
CY2022Q3	vani	Fair Value Of Liabilites Acquired FairValueOfLiabilitesAcquired	4064000	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	53262000	usd
CY2022Q3	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	8000000.0	usd
CY2022Q4	vani	Total Consideration TotalConsideration	54385000	usd
CY2022Q4	us-gaap	Advances Fair Value Disclosure AdvancesFairValueDisclosure	8000000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	-53262000	usd
CY2022Q4	vani	Gain On Bargain Purchase GainOnBargainPurchase	6877000	usd
CY2022	us-gaap	Sensitivity Analysis Of Fair Value Of Interests Continued To Be Held By Transferor Servicing Assets Or Liabilities Impact Of Other Than10 Or20 Percent Adverse Change In Prepayment Speed Percent SensitivityAnalysisOfFairValueOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrLiabilitiesImpactOfOtherThan10Or20PercentAdverseChangeInPrepaymentSpeedPercent	1	pure
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax	6900000	usd
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	700000	usd
CY2023	us-gaap	Utilities Operating Expense Operations UtilitiesOperatingExpenseOperations	2100000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zR3x5G0Rjrne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_868_zvGEg3p4kIz8">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred tax assets. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1300000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1400000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	17000000.0	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	14200000	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	300000	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	400000	usd
CY2023	vani	Grants Against Operating Expense GrantsAgainstOperatingExpense	500000	usd
CY2023	vani	Grants Against Operating Research And Development Expense GrantsAgainstOperatingResearchAndDevelopmentExpense	400000	usd
CY2023	vani	Grants Against Operatinggeneral And Administrative Expense GrantsAgainstOperatinggeneralAndAdministrativeExpense	100000	usd
CY2022	vani	Grants Against Operating Expense GrantsAgainstOperatingExpense	500000	usd
CY2022	vani	Grants Against Operating Research And Development Expense GrantsAgainstOperatingResearchAndDevelopmentExpense	400000	usd
CY2022	vani	Grants Against Operatinggeneral And Administrative Expense GrantsAgainstOperatinggeneralAndAdministrativeExpense	100000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zSWhJCXUjdrj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="xdx_861_z0ZNUfCQabR5">Concentration of Credit Risk</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Financial instruments that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and SIPC insurance limits of $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zbeL7yqt1faf" title="FDIC insured amount">250,000</span> and $<span id="xdx_906_ecustom--CashSPICInsuredAmount_iI_c20231231_zcsPyykkDpac" title="SPIC insured amount">500,000</span> (including cash of $<span id="xdx_90C_ecustom--SPICCashLimitCoverage_iI_c20231231_zYrmE7G0mVQf" title="SPIC cash limit coverage">250,000</span>), respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We also maintain cash at a bank in Switzerland. Accounts at said bank are insured up to an amount specified by the deposit insurance agency of Switzerland.</p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	vani	Cash Spic Insured Amount CashSPICInsuredAmount	500000	usd
CY2023Q4	vani	Spic Cash Limit Coverage SPICCashLimitCoverage	250000	usd
CY2023Q4	vani	Accrued Liabilities Current1 AccruedLiabilitiesCurrent1	0	usd
CY2022Q4	vani	Accrued Liabilities Current1 AccruedLiabilitiesCurrent1	50000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	9733	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	10311	shares
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	6091	shares
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	5272	shares
CY2023Q4	vani	Shares Underlying Restricted Stock Unit Outstanding SharesUnderlyingRestrictedStockUnitOutstanding	403	shares
CY2023Q4	vani	Shares Underlying Rsus SharesUnderlyingRsus	16227	shares
CY2022Q4	vani	Shares Underlying Rsus SharesUnderlyingRsus	15583	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	18629000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	44417000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4171000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3593000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2442000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2411000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1729000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1182000	usd
CY2023Q4	vani	Contract Liabilities Other ContractLiabilitiesOther	335000	usd
CY2022Q4	vani	Contract Liabilities Other ContractLiabilitiesOther	335000	usd
CY2018	vani	Grant Received To Support Clinical Development GrantReceivedToSupportClinicalDevelopment	1600000	usd
CY2018	vani	Grant Receivable To Fund Early Feasibility Clinical Trial For Five Years GrantReceivableToFundEarlyFeasibilityClinicalTrialForFiveYears	6400000	usd
CY2023	vani	Grants Against Operating Expenses GrantsAgainstOperatingExpenses	500000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	400000	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	100000	usd
CY2022	vani	Grants Against Operating Expenses GrantsAgainstOperatingExpenses	500000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	400000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	100000	usd
CY2022Q3	vani	Stock Issued During Period Shares Merger Acquisitions StockIssuedDuringPeriodSharesMergerAcquisitions	13136362	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.15
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3540216	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3540216	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	100000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1541000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1499000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	48170000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1864000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1296000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee	1383817	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.22
CY2023	vani	Share Based Compensation1 ShareBasedCompensation1	1200000	usd
CY2022	vani	Share Based Compensation1 ShareBasedCompensation1	1500000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	1101000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	1475000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	5120000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	2456000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Regulatory Assets And Liabilities DeferredTaxAssetsRegulatoryAssetsAndLiabilities	302000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Regulatory Assets And Liabilities DeferredTaxAssetsRegulatoryAssetsAndLiabilities	48000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	44749000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6770000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6319000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63004000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56546000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	1924000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	1510000	usd
CY2023Q4	us-gaap	Deferred Revenue Leases Accumulated Amortization DeferredRevenueLeasesAccumulatedAmortization	200000	usd
CY2022Q4	us-gaap	Deferred Revenue Leases Accumulated Amortization DeferredRevenueLeasesAccumulatedAmortization	202000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2124000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1712000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	60880000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54834000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	6046000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	4980000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-25652000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-13889000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5387000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2916000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-1791000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.070	pure
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-1073000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.077	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-1050000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.041	pure
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-707000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.051	pure
CY2022	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	-311000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.022	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	2184000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.085	pure
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	28000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.020	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6046000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.236	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4980000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.359	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	2000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	2000	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	47353000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	136332000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	183685000	usd
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	120068000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2518000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	7524000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5120000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	2500000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7500000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	262000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1430000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1692000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	usd
CY2023Q1	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	to lease 14,823 square feet of office space at 27200 Tourney Road, Valencia, California 91355.
CY2023Q1	us-gaap	Lessee Finance Sublease Option To Extend LesseeFinanceSubleaseOptionToExtend	The sublease has a term of two years and two months. We also entered into a lease for storage space on January 25, 2023, in the same building at a cost of $6,775 per month for a term of two years and one month.
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19616000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	779000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1383000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	955000	usd
CY2023Q4	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	19313000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2800000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	900000	usd
CY2023	us-gaap	Utilities Operating Expense Maintenance UtilitiesOperatingExpenseMaintenance	1100000	usd
CY2022	us-gaap	Utilities Operating Expense Maintenance UtilitiesOperatingExpenseMaintenance	300000	usd
CY2023	vani	Lessee Discounted Operating Lease Liability Payments Due Year Three LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearThree	3070000	usd
CY2023	vani	Lessee Discounted Operating Lease Liability Payments Due Year Four LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearFour	2914000	usd
CY2023	vani	Lessee Discounted Operating Lease Liability Payments Due Year Five LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearFive	2889000	usd
CY2023	vani	Lessee Discounted Operating Lease Liability Payments Due Year Six LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearSix	2976000	usd
CY2023	vani	Lessee Discounted Operating Lease Liability Payments Due Year Seven LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearSeven	3065000	usd
CY2023	vani	Lessee Discounted Operating Lease Liability Payments Due Year Eight LesseeDiscountedOperatingLeaseLiabilityPaymentsDueYearEight	15861000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	30775000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10079000	usd
CY2023	us-gaap	Lease Cost LeaseCost	20696000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0841	pure
CY2023	vani	Cash Paid For Operating Lease Liabilities CashPaidForOperatingLeaseLiabilities	1932000	usd
CY2022	vani	Cash Paid For Operating Lease Liabilities CashPaidForOperatingLeaseLiabilities	1049000	usd
CY2023	vani	Clinical And Regulatory Expense ClinicalAndRegulatoryExpense	100000	usd
CY2022	vani	Clinical And Regulatory Expense ClinicalAndRegulatoryExpense	200000	usd
CY2021Q2	vani	Liquidated Damages Paid Value LiquidatedDamagesPaidValue	1000000	usd
CY2023	us-gaap	Contract Termination Claims Description ContractTerminationClaimsDescription	Pixium indicated that it considered this termination wrongful, rejected the Company’s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately €5.1 million or about $5.6 million. We believe we have fulfilled our obligations to Pixium with the liquidated damages payment of $1,000,000.
CY2021Q2	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	1000000	usd
CY2021Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5600000	usd
CY2022Q4	us-gaap	Loss Contingency Settlement Agreement Court LossContingencySettlementAgreementCourt	On December 8, 2022, the Company received notice that the Paris Commercial Court has rendered its judgement, including finding that the Company’s termination of the MOU was not valid. In the judgment, the Company was ordered to pay to Pixium the amount of €2,500,000 minus a €947,780 credit for the $1,000,000 already paid for, a net amount payable of approximately €1,552,220. On May 24, 2023, the Company filed an appeal against the judgment from the Paris Commercial Court except in so far as such prior judgment dismissed (i) Pixium’s claim for the Company to pay it a sum of €480,693 relating to the alleged time spent by its teams, (ii) Pixium’s application to order the Company to pay it a sum of €1,500,000 in respect to alleged loss of opportunity and (iii) deducted the sum of $1,000,000 that we already paid Pixium and which Pixium retained. Thereafter Pixium filed its brief with Paris Court of Appeal and filed a cross-appeal on January 18, 2024. Meanwhile, the Company received notice that the Paris Commercial Court in its judgment dated January 31, 2024 converted Pixium’s receivership proceedings to liquidation proceedings and that Pixium’s liquidator is due to intervene in the pending proceedings before the Paris Court of Appeal. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022 related to this matter but plans to continue its appeal against the preliminary judgment.
CY2022	vani	Loss Contingency Settlement Agreement Court1 LossContingencySettlementAgreementCourt1	1675000	usd

Files In Submission

Name	View Source	Status
0001753926-24-000616-index-headers.html	Edgar Link	pending
0001753926-24-000616-index.html	Edgar Link	pending
0001753926-24-000616.txt	Edgar Link	pending
0001753926-24-000616-xbrl.zip	Edgar Link	pending
ex4_1img1.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g084109_10k.htm	Edgar Link	pending
g084109_ex10-4.htm	Edgar Link	pending
g084109_ex21-1.htm	Edgar Link	pending
g084109_ex23-1.htm	Edgar Link	pending
g084109_ex31-1.htm	Edgar Link	pending
g084109_ex31-2.htm	Edgar Link	pending
g084109_ex32-1.htm	Edgar Link	pending
g084109_ex4-1.htm	Edgar Link	pending
g084109_ex4-5.htm	Edgar Link	pending
g084109_ex97-1.htm	Edgar Link	pending
img0006.jpg	Edgar Link	pending
img001.jpg	Edgar Link	pending
img002.jpg	Edgar Link	pending
img003.jpg	Edgar Link	pending
img004.jpg	Edgar Link	pending
img005.jpg	Edgar Link	pending
img006.jpg	Edgar Link	pending
img007.jpg	Edgar Link	pending
img008.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vani-20231231.xsd	Edgar Link	pending
vani-20231231_def.xml	Edgar Link	unprocessable
vani-20231231_lab.xml	Edgar Link	unprocessable
vani-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
g084109_10k_htm.xml	Edgar Link	completed
vani-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VANI
Vivani Medical, Inc. Stock $vani

2024 Q1 Form 10-K Financial Statement

#000175392624000616 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VANI Vivani Medical, Inc. Stock $vani

2024 Q1 Form 10-K Financial Statement

#000175392624000616 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VANI
Vivani Medical, Inc. Stock $vani